secwatch.observer — SEC 8-K summary
======================================

Issuer:     LAVA Therapeutics NV (—)
CIK:        0001840748
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001104659-25-052460
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LAVA Therapeutics appoints KPMG as new auditor, dismisses PwC
-------------------------------------------------------------

- Board approved KPMG as independent auditor for FY2025, dismissing PwC effective May 20, 2025.
- PwC's reports for FY2023 and FY2024 were unqualified, with no adverse opinions or modifications.
- No accounting disagreements with PwC; prior material weaknesses in IT controls and segregation of duties were remediated as of Dec 31, 2024.
- PwC's letter agreeing with the statements is filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/0001104659-25-052460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/tm2515950d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer